PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma

Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with melanoma. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), was the first approved checkpoint inhibitor. Emerging long-term data indicate that approximately 20...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2015-02, Vol.6 (6), p.3479-3492
Hauptverfasser:	Luke, Jason J, Ott, Patrick A
Format:	Artikel
Sprache:	eng
Schlagworte:	Humans Immunotherapy - methods Melanoma - drug therapy Melanoma - immunology Melanoma - pathology Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!